Is a complete AKTX research report available?

No complete published report is available for Akari Therapeutics, Plc (AKTX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Akari Therapeutics, Plc (AKTX)

NASDAQ: AKTX · USD

$9.30

-0.51 (-5.2%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-24 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first AKTX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	16.3M
Net income (ttm)	-28M
EPS (ttm)	-$26.9
Shares out	1.8M
Volume	4,258
Beta	1.39
Price target	$28.4	+205.3%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -28M
EPS (ttm): -$26.9
Market cap: 16.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All AKTX indicators

Market & fundamental data

Available fields

172

Groups with data

Currency

USD

Showing 172 of 172 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001541157
Company name	Akari Therapeutics, Plc
Country	United States
Country code	US
Cusip	00972G405
Employees	6
Employees Change	-3%
Employees Change Percent	-33.33
Enterprise value	$14.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US00972G4055
Last refreshed	2026-07-24
Market cap	$16.3M
Market cap category	Nano-Cap
Price	$9.3
Price currency	USD
Sector	Healthcare
Sector PE	44.8
Sector PE Fwd	23.64
Sic	2834
Symbol	AKTX
Website	https://www.akaritx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-172.3%
FCF yield	-67%
P/B ratio	0.74x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-28M
Net Income Growth Years	1%
Profit Per Employee	$-4.7M
ROA	-17.97
Roa5y	-72.8
ROCE	-144.1
ROE	-155.3
Roe5y	-449.3
ROIC	-39.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-48.47%
Cagr1y	-79.43%
Cagr3y	-59.41%
Cagr5y	-63.06%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$33.9M
Cash	$2.8M
Current Assets	$3.6M
Current Liabilities	$13.4M
Debt	$732,000
Debt Equity	$0.05
Equity	$14.4M
Interest Coverage	-30.9
Liabilities	$19.5M
Long Term Assets	$30.3M
Long Term Liabilities	$6.1M
Net Cash	$2M
Net Cash By Market Cap	$12.51
Net Cash Growth	176.63%
Net Debt Equity	$-0.14
Tangible Book Value	$-15.9M
Tangible Book Value Per Share	$-13.91
WACC	15.81

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.27
Net Working Capital	$-11.9M
Quick ratio	0.21
Working Capital	$-9.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-143.97%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.87%
1Y total return	-79.41%
200-day SMA	13.34
3Y total return	-93.32%
50-day SMA	11.58
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.31%
All Time High	20,880
All Time High Change	-99.96%
All Time High Date	2015-09-28
All Time Low	3.02
All Time Low Change	208.46%
All Time Low Date	2026-05-12
ATR	1.87
Beta	1.39
Beta1y	4.36
Beta2y	1.47
Ch YTD	-19.55
High	10.03
High52	49.6
High52 Date	2025-09-25
High52ch	-81.25%
Low	9.11
Low52	3.02
Low52 Date	2026-05-12
Low52ch	208.46%
Ma50ch	-19.65%
Price vs 200-day SMA	-30.28%
RSI	40.7
RSI Monthly	32.39
RSI Weekly	44.3
Sharpe ratio	0.25x
Sortino ratio	0.78
Total Return	-143.97%
Tr YTD	-19.55
Tr1m	-17.19%
Tr1w	-19.13%
Tr3m	60.62%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Count Top	0
Analyst Ratings	Buy
Earnings EPS Estimate	$-0.69
Operating Income	$-12.2M
Price target	$28.39
Price Target Change	$205

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,077,647%
Float Percent	61.57%
Net Borrowing	1,426,000
Shares Insiders	32.15%
Shares Institutions	3.45%
Shares Out	1,750,409
Shares Qo Q	37.44%
Shares Yo Y	143.97%
Short Ratio	0.17
Short Shares	1.96

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-13.1M
Average Volume	84,572.35x
Bv Per Share	12.56
Ch10y	-99.87
Ch1m	-17.19
Ch1w	-19.13
Ch1y	-79.41
Ch3m	60.62
Ch3y	-93.32
Ch5y	-99.31
Ch6m	-13.38
Change	-5.2%
Change From Open	2.09
Close	9.81
Days Gap	-7.14
Dollar Volume	39,599.4
Earnings Date	2026-08-12
Earnings Time	amc
EBIT	$-29.5M
EBITDA	$-29.5M
EPS	$-26.91
F Score	2
FCF	$-10.9M
FCF EV Yield	-76.57x
FCF Per Share	$-6.23
Financing CF	11,091,000
Fiscal Year End	December
Income Tax	$-1.9M
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-19
Last Report Date	2026-03-31
Last Split Date	2026-03-31
Last Split Type	Reverse
Last10k Filing Date	2026-03-30
Ma150	9.39
Ma150ch	-0.99%
Ma20	11.45
Ma20ch	-18.76%
Net CF	186,000
Next Earnings Date	2026-08-12
Open	9.11
Optionable	No
Position In Range	20.65
Price Date	2026-07-23
Relative Volume	0.05x
Share Based Comp	2,180,000
Tr6m	-13.38%
Us State	Florida
Volume	4,258

Akari Therapeutics, Plc (AKTX)

Coverage state: Market snapshot only — no published research

Generate the first AKTX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · AKTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AKTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on AKTX

Frequently asked questions